Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765583 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.
A Phase 4 study of Rhytids, sponsored by Medicis Aesthetics.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT00765583: Completed Phase 4 study of Rhytids, sponsored by Medicis Aesthetics.
NCT00765583 is a Phase 4 study of Rhytids that has completed, run by Medicis Aesthetics. The registered enrollment target is 75 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00765583, a Phase 4 study of Rhytids, has completed, sponsored by Medicis Aesthetics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
A total of 75 subjects will be enrolled into a 36 month study. Subjects will be treated with Restylane® on both sides of the face (nasolabial folds) at the first visit, on one side of the face at month 4.5 and on the other side of the face at month 9. Both sides of the face will then be treated again at month 18. The subjects will evaluate themselves and will also be evaluated by the treating doctor and a blinded evaluator (a person that does not know when the different sides of the face are treated). Side effects and medications taken during the study will also be recorded.
Conditions Studied
Interventions
- DRUG Restylane
Study Locations (3)
Florida
- Dermatology Research Institute, LLC - Coral Gables
Illinois
- Dayan Facial Plastic Surgery Institute - Chicago
New York
- Rhoda Narins, MD - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
What the finished NCT00765583 record still lists
NCT00765583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Rhytids appearing as the primary indexed condition, and to 1 intervention - of which Restylane is the first listed.
NCT00765583 reports a single indexed study location in Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00765583 about?
NCT00765583 is a clinical study titled "A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.". A total of 75 subjects will be enrolled into a 36 month study. Subjects will be treated with Restylane® on both sides of the face (nasolabial folds) at the first visit, on one side of the face at month 4.5 and on the other side of the face at month 9. Both sides of the face will then be treated agai...
What is the current status of trial NCT00765583?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2005-11. Estimated completion is 2009-02.
What conditions does trial NCT00765583 study?
This clinical trial studies the following conditions: Rhytids.
What interventions are being tested in trial NCT00765583?
The interventions under investigation include: Restylane (DRUG).
Who is sponsoring clinical trial NCT00765583?
This trial is sponsored by Medicis Aesthetics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00765583 being conducted?
This trial has 3 study locations across Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhytids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00765583's enrollment target sits among peer trials
75 1002nd of 2000 higher than 975 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia